Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cardiovascular Toxicity of Proteasome Inhibitors: Underlying Mechanisms and Management Strategies
Georgios Georgiopoulos, Nikolaos Makris, Ageliki Laina, et al.
JACC CardioOncology (2023) Vol. 5, Iss. 1, pp. 1-21
Open Access | Times Cited: 50

Showing 1-25 of 50 citing articles:

Cardiovascular disease and cancer: shared risk factors and mechanisms
Nicholas S. Wilcox, Uri Amit, Jacob B. Reibel, et al.
Nature Reviews Cardiology (2024) Vol. 21, Iss. 9, pp. 617-631
Closed Access | Times Cited: 75
Cardiovascular Considerations After Cancer Therapy
Anne Blaes, Anju Nohria, Saro H. Armenian, et al.
JACC CardioOncology (2025) Vol. 7, Iss. 1, pp. 1-19
Open Access | Times Cited: 2
Large-scale multi-omics identifies drug targets for heart failure with reduced and preserved ejection fraction
Danielle Rasooly, Claudia Giambartolomei, Gina M. Peloso, et al.
Nature Cardiovascular Research (2025)
Closed Access | Times Cited: 2
Repurposing proteasome inhibitors for improved treatment of triple-negative breast cancer
Peter Larsson, Daniella Pettersson, Maxim Olsson, et al.
Cell Death Discovery (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 10
Cardiotoxicity of Anticancer Drugs: Molecular Mechanisms, Clinical Management and Innovative Treatment
Feiyu Gao, Tao Xu, F Zang, et al.
Drug Design Development and Therapy (2024) Vol. Volume 18, pp. 4089-4116
Open Access | Times Cited: 9
Blood pressure variability as predictor of cancer therapy-related cardiovascular toxicity in patients with Multiple Myeloma
Elvira Fanelli, Giulia Picca, Lorenzo Airale, et al.
Hypertension Research (2025)
Closed Access | Times Cited: 1
Cardiovascular Considerations Before Cancer Therapy
Zahra Raisi‐Estabragh, A. Murphy, Sivatharshini Ramalingam, et al.
JACC CardioOncology (2024) Vol. 6, Iss. 5, pp. 631-654
Open Access | Times Cited: 7
Drug-induced atrial fibrillation. A narrative review of a forgotten adverse effect
Juan Tamargo, Julián Pérez‐Villacastín, Ricardo Caballero, et al.
Pharmacological Research (2024) Vol. 200, pp. 107077-107077
Open Access | Times Cited: 6
Cancer Therapy-Associated Pulmonary Hypertension and Right Ventricular Dysfunction: Etiologies and Prognostic Implications
Orly Leiva, William Beaty, Steven Soo, et al.
Reviews in Cardiovascular Medicine (2024) Vol. 25, Iss. 3, pp. 87-87
Open Access | Times Cited: 5
Characteristics and outcomes of patients developing pulmonary hypertension associated with proteasome inhibitors
Julien Grynblat, Charles Khouri, Alex Hlavaty, et al.
European Respiratory Journal (2024) Vol. 63, Iss. 6, pp. 2302158-2302158
Closed Access | Times Cited: 5
Overcoming proteasome inhibitor resistance in the immunotherapy era
Bonell Patiño-Escobar, Alexis Talbot, Arun P. Wiita
Trends in Pharmacological Sciences (2023) Vol. 44, Iss. 8, pp. 507-518
Open Access | Times Cited: 12
A New target of ischemic ventricular arrhythmias—ITFG2
Qing-ming Pan, Fangfang Bi, Ze-hong Jing, et al.
European Journal of Pharmacology (2025), pp. 177301-177301
Closed Access
Risk Assessment Prior to Cardiotoxic Anticancer Therapies in 7 Steps
Jieli Tong, Isabelle Senechal, Sivatharshini Ramalingam, et al.
British Journal of Hospital Medicine (2025), pp. 1-21
Closed Access
Cardiovascular outcomes and mortality in diabetic multiple myeloma patients initiated on proteasome inhibitors according to prior use of glucagon-like peptide 1 agonists
Yu‐Cheng Chang, Chun-Yu Peng, Kuan‐Yu Chi, et al.
European Journal of Preventive Cardiology (2025)
Closed Access
Identifying common pathways for doxorubicin and carfilzomib-induced cardiotoxicities: transcriptomic and epigenetic profiling
C. Kelly, Dylan J. Kiltschewskij, Angeline J.W. Leong, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
The effect of proteasome in heart transplantation: From mechanisms to therapeutic potential
Ye Zhou, Yu Chen, Mengyao Xu, et al.
Life Sciences (2025) Vol. 364, pp. 123446-123446
Closed Access
Moving the Therapeutic Needle in Immunoglobulin Light Chain and TTR Cardiac Amyloidosis
Morie A. Gertz
American Journal of Hematology (2025)
Closed Access
Lentinan alleviates angiotensin II-induced myocardial remodeling through LMP7-SOCS3 signaling
Yu Pan, Bingqi Chen, Jiawen Xie, et al.
International Journal of Biological Macromolecules (2025), pp. 142146-142146
Closed Access
Deterioration of Myocardial Global Longitudinal Strain and Its Relationship with Arterial Stiffness in Patients with Cardiac Amyloidosis: A Six-Month Follow-Up
D Korela, Emmanouil Foukarakis, A Plevritaki, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 6, pp. 2078-2078
Open Access
Carfilzomib in multiple myeloma: unraveling cardiac toxicities - from mechanisms to diagnosis and management
Yi Gao, Di Zhou, Xue Bai, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access
Chemically Induced Hypertension: Antineoplastic Agents Associated with High Blood Pressure
Emily Moss, Anushree C. Shirali
Updates in hypertension and cardiovascular protection (2025), pp. 79-91
Closed Access
Impact of blood pressure variability on the prediction of cancer therapy-related cardiovascular toxicity in patients with multiple myeloma
Satoshi Morimoto, Atsuhiro Ichihara
Hypertension Research (2025)
Closed Access
Targeted protein degradation for cancer therapy
Matthias Hinterndorfer, Valentina A. Spiteri, Alessio Ciulli, et al.
Nature reviews. Cancer (2025)
Closed Access
Management of hypertension in patients with cancer: challenges and considerations
Shubhi Pandey, Amar Kalaria, Kenar D. Jhaveri, et al.
Clinical Kidney Journal (2023) Vol. 16, Iss. 12, pp. 2336-2348
Open Access | Times Cited: 9
Cardio-Oncology and Heart Failure: A Scientific Statement from the Heart Failure Society of America
Michelle Bloom, Jacqueline B. Vo, Jo E. Rodgers, et al.
Journal of Cardiac Failure (2024)
Closed Access | Times Cited: 3
Page 1 - Next Page

Scroll to top